Last reviewed · How we verify
NCT05112731: AGLIANICO
Role of Glycation and Inflammation in Acute Ischemic Heart Disease
trial testing BAFF and MGO in Myocardial Infarction in 16 participants. Terminated before completion.
31 December 2023
Quick facts
| Lead sponsor | GEK Srl |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 1 February 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- BAFF and MGO
Conditions studied
- Myocardial Infarction — all drugs for Myocardial Infarction →
- Glycation End Products, Advanced — all drugs for Glycation End Products, Advanced →
- Inflammation — all drugs for Inflammation →
- Heart Injuries — all drugs for Heart Injuries →
Sponsor
GEK Srl
Who can join
Adults 18 to 80, any sex, with Myocardial Infarction or Glycation End Products, Advanced. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Glycation in the cardiomyocyte.
Delligatti CE, Kirk JA. · · 2024 · cited 5× · PMID 38997172 · DOI 10.1016/bs.vh.2024.04.005
Verify or expand the search:
- PubMed search for NCT05112731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myocardial Infarction
Currently open trials in the same condition.
- NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
- NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
- NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
- NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
- NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting
Other GEK Srl trials
Trials by the same sponsor.
- NCT04348760 — Study of Inflammatory Markers and Symptom Severity in Personalized Nutritional Intervention in IBS · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05112731 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GEK Srl
- Last refreshed: 16 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05112731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing